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Abstract
Background: Posaconazole is now widely used for
prophylaxis of invasive fungal infections in immuno-
compromised patients. The pharmacokinetic proper-
ties of the drug argue for therapeutic monitoring, but
so far described analytical methods have shortcom-
ings with respect to application in a routine setting.
The aim of our work was to develop an analytical
method suitable for routine use.
Methods: Liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) was used. For sample prepara-
tion, protein precipitation followed by on-line solid
phase extraction was used. SCH 56984, a posacona-
zole related compound provided by the manufacturer
of posaconazole, was used as internal standard.
Results: The method was characterized by short
hands-on time and an analytical run time of four
minutes. Validation data demonstrated acceptable
analytical performance.
Conclusions: LC-MS/MS with on-line solid phase
extraction for sample preparation allows the imple-
mentation of a convenient and reliable method for
pharmacokinetic monitoring of posaconazole.
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Introduction
Invasive fungal infections, most frequently caused by
Candida spp. and Aspergillus spp. are a leading cause
of mortality in severely immunocompromised hema-
to-oncological patients (1). Therefore, prophylaxis of
such infections has a very high priority in the care of
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these patients (2). Itraconazole is widely used for this
purpose in neutropenic hematological patients; its
use, however, is hampered by rather poor and varia-
ble enteral absorption of the oral formulation and var-
iable hepatic metabolism. Due to these pharmaco-
kinetic characteristics, therapeutic drug monitoring of
itraconazole is useful, with target concentration for
trough levels above 500 mg/L (3). Posaconazole (SCH
56592) is a structural homologue of itraconazole; two
chlorine atoms are exchanged by fluorine and one
OH-function is added. The drug has recently been
introduced for prophylaxis of invasive fungal infec-
tions (4, 5). In two randomised phase III trials, the
therapeutic efficacy of posaconazole in the prevention
of fungal infection in patients with acute leukemia and
graft-vs.-host-disease has been demonstrated (6, 7).
Posaconazole is available only as an oral suspension,
but its absorption appears to be superior to that of
itraconazole. However, absorption is greatly influ-
enced by the dosing regimen that is used; for exam-
ple, twice vs. four times a day dosing for treatment of
invasive fungal infections, three times a day dosing
for antifungal prophylaxis, or the effect of fat content
of concomitant meals (8, 9). Typical steady state pre-
dose concentrations, maximum concentrations and
average concentrations of posaconazole are approxi-
mately between 200 and 900 mg/L (10). The drug does
not undergo metabolism by cytochrome P450 (CYP)
enzymes and -30% of an administered dose is typi-
cally metabolised, usually by glucuronidation. The
compound is primarily excreted into bile (5). Thus, the
pharmacokinetic characteristics of posaconazole
seem more favorable compared to itraconazole (5).
However, monitoring of posaconazole concentrations
in plasma may be important, particularly in the con-
text of future clinical trials in selected groups of indi-
viduals such as pediatric patients (11). The availability
of a routine method for the quantification of posaco-
nazole plasma concentrations may be helpful for
patients with severely impaired enteral absorption
due to graft-vs-host disease, impaired excretory
hepatic function or questionable compliance with
drug administration requirements.
The technique of liquid chromatography-tandem
mass spectrometry (LC-MS/MS) offers very high spec-
ificity and sensitivity, with a short turn-around time,
limited requirements of sample preparation, and
good practicality. This technology has become avail-
able in a growing number of tertiary care hospitals
worldwide, despite the high instrument cost. The aim
of our work was to develop a convenient LC-MS/MS
method for the quantification of plasma posaconazole
concentrations. We applied automated on-line solid
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Figure 1 Molecular structure of posaconazole (A) and of the
internal standard compound SCH 56984 (B).
Figure 2 Collision induced disintegration spectrum of posa-
conazole (A), and internal standard compound SCH 56984 (B)
recorded at a collision energy of 29 V.
Posaconazole (not fully disintegrated) precursor ion, 701.4
m/z; product ion selected for MRM monitoring, 683.5 m/z.
SCH 56984 (not fully disintegrated) precursor ion, 687.3
m/z; product ion selected for MRM monitoring, 669.0 m/z.
phase extraction prior to mass spectrometric analysis
since this approach allows for a more robust and
simple technique for a variety of analytes.
Materials and methods
Analytical procedure
Chemicals Posaconazole and the compound SCH 56984, a
homology of posaconazole, were used as internal standard
(Figure 1A and B). These were obtained from the Schering-
Plough Research Institute (Kenilworth, NJ, USA). The lots of
posaconazole and SCH 56984 were analysed by Schering-
Plough, and XenoBiotic Laboratories Inc., respectively
(Plainsboro, NJ, USA). These laboratories certified that the
purity was )98%. Stock solutions of these compounds were
made in methanol (50 mg/L). Methanol and water were of
HPLC-grade (Baker, Deventer, The Netherlands); formic acid
was from Merck (Darmstadt, Germany).
Instruments A Waters Alliance 2795 HPLC module (Waters,
Milford, USA) was used, coupled with a split of approxi-
mately 1:10 to a Micromass Quattro LC tandem mass spec-
trometry system (Waters, Manchester, UK).
Mass spectrometric conditions
Electrospray ionization in the positive mode was used.
Source parameters were tuned to obtain the protonated
quasi-molecular ions (wMqHqx) of posaconazole (701.4 m/z)
and of the internal standard compound SCH 56984 (687.3
m/z), respectively. The following settings resulted in optimal
ion yield: capillary voltage, 3.5 kV; cone voltage, 57 V; source
temperature, 908C; desolvation temperature, 2808C; nitrogen
flow, ;800 L/h; cone gas flow, ;75 L/h. The collision energy
with argon as the collision gas was 32 V. With these condi-
tions, several intense product ions were generated for both
analytes (Figure 2A and B). For quantification the following
multiple-reaction monitoring (MRM) transitions were record-
ed: posaconazole 701.4)683.5, SCH 56984 (internal stan-
dard) 687.3)669.0. The dwell time for all MRM traces was
0.15 s. Representative chromatograms are given in Figure 3.
Calibration and quality control materials
A three-point set of lyophilised calibrators from Chromsys-
tems (Munich, Germany) was used together with three levels
of lyophilised quality control samples from the same source.
Calibrator concentrations were 570, 2280 and 5570 mg/L.
Sample preparation and chromatography
A semi-automated sample preparation protocol with a man-
ual protein precipitation step and automated on-line solid
phase extraction employing column-switching was used.
Into 1.5 mL polypropylene cups, 50 mL of calibrator or
patient sample was precipitated with 200 mL of methanol/
acetonitrile (90/10) containing the internal standard com-
pound SCH 56984 at a concentration of 200 mg/L. Following
vigorous vortex mixing, specimens were centrifuged for
10 min at 15,000 g using a non-thermostated standard bench
top centrifuge. Next, 100 mL of the clear supernatant was
transferred into HPLC vials and placed into the HPLC
autosampler.
For on-line solid phase extraction, a Waters Oasis HLB
column (25 mm, 2.1=20 mm; Waters, Milford, USA) was
used, together with a six-port high-pressure switching
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Figure 3 Representative chromatograms.
(A) Patients’ plasma (posaconazole concentration 588 mg/L);
(B) plasma sample spiked to a concentration of 30 mg/L;
(C) drug-free sample.
Figure 4 Scheme of the on-line solid phase extraction
system.
AC, analytical column; W, waste; MS, mass spectrometry
system.
valve (Rheodyne, Rohnert Park, CA, USA) controlled by the
Micromass MassLynx 4.0 mass spectrometry software
(Waters, Milford, USA).
The automated extraction procedure consisted of three
steps. First 50 mL of deproteinized sample was injected and
loaded onto the extraction column in valve position A (Figure
4). The mobile phase was water/methanol 90/10 (v/v), deliv-
ered at a flow rate of 4 mL/min. Potentially interfering
compounds were washed into the waste. In parallel, the
analytical column (LiChrospher C18 endcaped 5 mm,
77=4 mm; Dr. Maisch, Germany) was equilibrated with
methanol/0.1% formic acid 90/10 (v/v) delivered at a flow rate
of 0.9 mL/min. After 1 min, the switching valve was changed
to position B; the extraction column was now eluted in a
back-flush mode onto the analytical column. After another
2 min, the valve was switched back to position A. During the
analytical chromatography into the mass spectrometer in
position A, the extraction column was washed with aceto-
nitrile/methanol 50/50 (v/v) at a flow rate of 4 mL/min for
1 min and the extraction column subsequently re-equilibrat-
ed with water/methanol 90/10 (v/v). Both the extraction col-
umn and analytical column were kept at 388C in the column
oven. The retention times of posaconazole and the internal
standard SCH 56984 were ;1.8 min after injection onto the
extraction column. The total analytical run-time was 4 min.
For quantification, the peak area-ratios of the MRM trace
of posaconazole and the internal standard compound SCH
56984 were assessed. We did not apply fit weighting or axis
transformation.
Validation
We evaluated the recovery of the two-step extraction pro-
cess and assessed potential ion-suppression effects. A pure
solution of posaconazole (200 mg/L) in water/methanol 90/10
(v/v) was introduced into the mass spectrometer by direct
injection onto the analytical column, in triplicate. The mobile
phase consisted of methanol/0.1% formic acid 90/10 (v/v),
and we did not apply on-line solid phase extraction. We used
residual clinical samples from 10 intensive care patients not
receiving posaconazole to prepare a posaconazole-free
plasma pool. We spiked this pool with posaconazole to
obtain a concentration of 200 mg/L. The spiked pool was sub-
mitted in triplicate to the entire analytical process including
protein precipitation and automated solid phase extraction.
The mean peak areas of the MRM trace of posaconazole for
the directly analysed pure solution and for the extracted
spiked plasma sample, respectively, were compared.
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Table 1 Results of the method validation study.
QC level I QC level II QC level III Pool
Target concentration 250 mg/L 1050 mg/L 4190 mg/L
Measured concentration (mean) 245 mg/L 1066 mg/L 4298 mg/L 644 mg/L
Coefficient of variation 5.8% mg/L 5.4% mg/L 5.1% mg/L 9.7% mg/L
Accuracy (mean concentration) –2.1% q1.5% q2.6%
Accuracy (range) –11.8%"3.9% –7.2%"8.2% –6.2%"11.4%
To verify the specificity of the method, 20 residual plasma
samples from patients not treated with posaconazole were
analysed. We omitted the addition of internal standard com-
pound to the precipitation solution. MRM chromatograms of
posaconazole and the internal standard were inspected for
peak signals.
Reproducibility, accuracy and linearity of the method were
investigated in three analytical series. Quality control mate-
rials at three concentrations and aliquots of a plasma pool
from posaconazole-treated patients were quantitated in
quadruplicated.
In order to verify the sensitivity of the analytical system at
low and sub-therapeutic concentrations, a drug-free plasma
was spiked to a concentration of 30 mg/L and the signal to
noise ratio was measured for three injections.
Carry over was evaluated by spiking the supernatant of a
drug-free plasma sample to a posaconazole concentration of
10,000 mg/L and injected in quadruplicate. The chromato-
gram of this sample was inspected for peaks in the MRM
trace of posaconazole.
The stability of precipitation extracts was evaluated by
reanalysis of deproteinized samples of a calibration series,
24 h after their initial analysis. The peak areas were com-
pared between these two runs.
Results
The mean peak area for the MRM trace of posacona-
zole was 803.491 for 200 mg/L posaconazole in water/
methanol, injected without extraction procedure. The
mean peak area for a spiked plasma sample contain-
ing 200 mg/L posaconazole and submitted to the
entire analytical process was 768.649. This corre-
sponds to a signal recovery of 95.7%.
We evaluated 20 plasma samples from patients
who were not treated with posaconazole. We observ-
ed no peak signals in the MRM traces of the analyte
and its internal standard SCH 56984, respectively.
Results for our investigations of imprecision and
accuracy are shown in Table 1. The total coefficient of
variation was -6%, and accuracy based on quadru-
plicate analysis of three quality control samples
ranged from –11.8% to 11.4%. The CV for the sample
pool was 9.7% and the coefficient for measurement
of the calibrators revealed an r value of )0.99 for all
validation series.
Evaluation of our plasma sample spiked to obtain a
posaconazole concentration of 30 mg/L showed a
mean signal to noise ratio of 48:1. A chromatogram
of this sample is shown in Figure 3B.
No carry-over effect was noted. Extracts obtained
by protein precipitation were found to be stable for at
least 24 h. Chhun et al. (12) has previously reported
detailed data on the stability of posaconazole in
plasma. We have found our method to be robust after
routine use for six months.
Discussion
We describe a convenient high-throughput LC-MS/MS
method for the quantification of posaconazole in
human plasma samples. Using commercially avail-
able materials for calibration and quality control,
validation data demonstrated our method to be com-
patible with the analytical performance level required
for use in the routine clinical laboratory. However,
CVs above 5% and accuracies )"5% do not charac-
terize the assay as extraordinarily accurate, as might
be expected for a mass spectrometric assay. This
observation, however, is typical for a number of LC-
MS/MS assays used in clinical pharmacology. For the
majority of these analytes, no stable-isotope labeled
internal standard compounds are available and struc-
turally related ‘‘homologue’’ molecules have to be
used instead. Often, there is sensitivity drift due to
‘‘charging’’ of the ion source or of the ion optics. This
phenomenon seems to affect the target analyte and
corresponding internal standard to a different degree,
potentially resulting in limitations in accuracy of LC-
MS/MS methods.
The availability of an appropriate internal standard
is critical for the implementation of LC-MS/MS assays
for therapeutic drug monitoring. We tried to use fen-
buconazole, a commercially available agrochemical
antimycotic azole compound, as the internal standard
for quantification of posaconazole. Although similar in
molecular structure, the ionization behavior of this
compound is too different from that of posaconazole
to be successfully applied as the internal standard.
We observed unacceptable reproducibility (CV)15%)
and linearity (r-0.95) when using fenbuconazole as
the internal standard for quantification of posacona-
zole. Development of the present method was only
possible after obtaining SCH 56984 from the manu-
facturer of posaconazole. SCH 56984 is a closely relat-
ed compound of posaconazole that we used as the
internal standard. Unfortunately, this compound is
not commercially available at present. Our observa-
tion that fenbuconazole was not applicable for use as
the internal standard for quantitation of posaconazole
might be instrument specific. The development and
validation of an LC-MS/MS method using one specific
instrument may not be easily transferable to another
similar instrument. Even for methods developed for
one specific instrument, changes in the performance
characteristics due to, for example, contamination of
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the ion source or the mass analyzer, or accumulation
of late eluting matrix compounds such as phospholip-
ids on the analytical column causing ion suppression,
may compromise the validity of the results if no sta-
ble isotope-labeled internal standard compound is
available. Therefore, strict adherence to good quality
assurance practices during development and appli-
cation of LC-MS/MS methods is critical.
High analytical specificity, simple sample prepara-
tion, and high throughput are typical strengths of
LC-MS/MS technology used for therapeutic drug
monitoring (13). High analytical precision is, however,
not a strength of this technology. It is well recognized
that individual HPLC-UV methods may be superior to
LC-MS/MS methods with respect to precision.
Several HPLC methods for the quantitation of posa-
conazole in human plasma employing ultraviolet
detection have been described previously (14–16).
These methods require laborious sample preparation
along with extensive chromatographic run times. In
addition, a major limitation of conventional HPLC
methods that rely on UV detection is the questionable
specificity for individual samples. Analytical speci-
ficity of HPLC-UV methods can be evaluated for inter-
ference from endogenous compounds as well as
commonly used compounds that may be co-admin-
istered with the drug being measured. However,
spurious results caused by co-elution of interfering
exogenous compounds with the analyte or internal
standard compound is a potential problem with this
method of detection. With respect to specificity, LC-
MS/MS, although requiring substantially more expen-
sive instrumentation, has emerged as the standard
technology for therapeutic drug monitoring and is
replacing HPLC-UV methods in a growing number of
clinical laboratories.
Three mass spectrometric methods for the quanti-
fication of posaconazole in human plasma have been
published previously (16–18). Some of these methods
are laborious, employing solvent extraction with an
evaporation step (18). Others require robotic sample
preparation systems (16, 17). In terms of practicabi-
lity, the method we describe is superior to these
previous methods since only protein precipitation is
needed as the manual sample preparation step. This
is next followed by automated solid phase extraction
with a permanently used extraction cartridge employ-
ing standard chromatography equipment. This tech-
nique of on-line solid phase extraction has been
applied to a variety of LC-MS/MS methods. We have
previous extensive experience with therapeutic drug
monitoring of immunosuppressants and itraconazole
(19, 20). Applying this straightforward principle of
sample clean-up, efficient control of ion suppression
effects and a very high degree of technical robustness
can be realized for high-throughput routine methods.
This technology also helps minimize the health haz-
ards associated with exposure to organic solvents
used in solvent extraction protocols, and is far more
economical compared with single-use solid phase
extraction cartridges.
In summary, our results suggest that the semi-auto-
mated LC-MS/MS method we describe is applicable
for monitoring of posaconazole plasma concentra-
tions in large-scale clinical studies, as well as for rou-
tine therapeutic drug monitoring.
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